Here, we describe the development and application of a gel contraction assay for evaluating contractile function in mesenchymal cells that underwent epithelial-mesenchymal transition.
Fibrosis is often involved in the pathogenesis of various chronic progressive diseases such as interstitial pulmonary disease. Pathological hallmark is the formation of fibroblastic foci, which is associated with the disease severity. Mesenchymal cells consisting of the fibroblastic foci are proposed to be derived from several cell sources, including originally resident intrapulmonary fibroblasts and circulating fibrocytes from bone marrow. Recently, mesenchymal cells that underwent epithelial-mesenchymal transition (EMT) have been also supposed to contribute to the pathogenesis of fibrosis. In addition, EMT can be induced by transforming growth factor β, and EMT can be enhanced by pro-inflammatory cytokines like tumor necrosis factor α. The gel contraction assay is an ideal in vitro model for the evaluation of contractility, which is one of the characteristic functions of fibroblasts and contributes to wound repair and fibrosis. Here, the development of a gel contraction assay is demonstrated for evaluating contractile ability of mesenchymal cells that underwent EMT.
Fibrosis is involved in the pathogenesis of various chronic progressive diseases, such as interstitial pulmonary disease, cardiac fibrosis, liver cirrhosis, terminal renal failure, systemic sclerosis, and autoimmune disease1. Among interstitial lung diseases, idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease and shows poor prognosis. Pathological hallmark of IPF is the development of fibroblastic foci consisting of activated fibroblasts and myofibroblasts that are associated with the prognosis. The origins of such pulmonary fibroblasts are proposed to be derived from several mesenchymal cells, including originally resident pulmonary fibroblasts and circulating fibrocytes from bone marrow. Recently, epithelial-mesenchymal transition (EMT) has been proposed to be associated with the formation of mesenchymal cells2, and to contribute to the pathogenesis of fibrotic disorders.
It is thought that EMT plays important roles in the process of fetal development, wound healing, and progression of cancer, including tumor invasion and metastasis3. Following the process of EMT, epithelial cells obtain the ability of mesenchymal cells by loss of epithelial markers, such as E-cadherin, and by expression of mesenchymal markers, such as vimentin, and α-smooth muscle actin (SMA)4,5. Previous studies showed the evidence that EMT process has been associated with the development of tissue fibrosis in the kidney6 and lung7. Additionally, chronic inflammation promotes fibrotic disease8; furthermore, such inflammatory cytokines as Tumor necrosis factor superfamily member 14 (TNFSF14; LIGHT), tumor necrosis factor (TNF)-α, and interleukin-1β, have been shown to enhance EMT9-12.
Collagen gel contraction assay, a collagen-based cell contraction assay in which fibroblasts are embedded in type I collagen gel three-dimensionally, is an ideal in vitro model for the evaluation of contractility. Contractility is one of the characteristic functions of fibroblasts and contributes to normal wound repair and fibrosis13. In this assay, it is thought that the attachment of fibroblasts to type I collagen through integrin-dependent mechanisms is supposed to produce mechanical tension under some conditions, and consequently lead to tissue contraction.
Here, the development of the gel contraction assay is reported to be adapted to evaluate the acquisition of contractile function in the cells that underwent EMT. This report demonstrates that this modified assay is suitable for evaluating contractility in mesenchymal cells that underwent EMT.
1. Preparations and Culture of Lung Epithelial Cells
2. EMT Procedure
3. Confirmation of EMT Procedure by PCR and Western Blotting
4. Gel Contraction Assay for Evaluating EMT
5. Measurement of Gel Size
During EMT, epithelial cells lose epithelial markers, like E-cadherin, and gain the expression of mesenchymal markers, such as vimentin and α-smooth muscle actin4,5. Incubation of A549 human lung epithelial cells with TGF-β1 and TNF-α induces EMT. The appearance of normal A549 cells are cobble stone like shape and triangle shape that is a characteristic of epithelial cells (Figure 3A), but after stimulated with TGF-β1 and TNF-α, the appearance changed to long spindle shape that is similar to mesenchymal cells (Figure 3B).
The expression of epithelial and mesenchymal markers was evaluated to confirm that cells underwent EMT. Relative mRNA expression was calculated with ΔΔCt method. Individual data was normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that is a housekeeping gene. A549 cells treated with TGF-β1 and TNF-α for 48 hr had significantly reduced expression of CDH1 and significantly increased expression of VIM and ACTA2 (Figure 4A). The primers sequences used for q-PCR are shown in Table1. As shown in Figure 4B, stimulation with TGF-β1 and TNF-α attenuated E-cadherin expression, whereas the expression of vimentin, N-cadherin, and α-smooth muscle actin was induced.
The gel contraction assay was performed to evaluate the contractility of cells that underwent EMT. After inducing EMT with TGF-β1 and TNF-α, cells were cast into the collagen gel and incubated for 72 hr in media containing TGF-β1 and TNF-α, or PBS. As shown in Figure 5A, the gels containing cells treated with TGF-β1 and TNF-α were smaller than control gels containing cells treated with PBS. To quantify the changes in gel size, gels were analyzed using a gel analyzer 0, 24, 48, and 72 hr after treatment. After 72 hr, the sizes of gels containing cells treated with TGF-β1 and TNF-α were significantly reduced compared to the control gels (Figure 5B). We also confirmed that the gels containing cells treated with TGF-β1 alone were smaller than control gels but were not smaller than the gels treated with TGF-β1 and TNF-α (data not shown).
Figure 1. Supplementary Figure for Making Gels. These images show the gels cast into wells. The gel medium containing the cells is viscous and can easily gel and form crescent shape in the well. (A) The left image shows that the gels are casted correctly, and the right image shows the schema of "neat cylindrical form". (B)The left image shows that the gels deform, and the right image shows that air bubbles contaminate the gels. (C) The gels are soft, so easily damaged and usually deform like "Pac-Man". Please click here to view a larger version of this figure.
Figure 2. The Steps for Measuring the Gel Size. (A) The gel documentation system consists of a PC and a gel imaging system. (B) The "image acquisition button", and a picture of the gels. (C) The "detection button", and the window for adjusting the measurement region (yellow circle). (D) The "auto-detection button", and the software makes a heatmap of the gels from a picture to detect the outline of the gels. (E) The software extracts the outline of the gels by image processing, and calculates areas surrounded by the outline. Please click here to view a larger version of this figure.
Figure 3. Morphologies of EMT-induced Cells. A549 human lung epithelia were plated at a density of 1.0 × 105 cells/well in a 6-well plate and incubated with or without 5 ng/ml TGF-β1 and 10 ng/ml TNF-α for 48 hr, followed by phase contrast microscopic imaging. (A) and (B) are images obtained under ×200. The scale bars in (A) and (B), 100 µm. Please click here to view a larger version of this figure.
Figure 4. EMT Stimulation with TGF-β1 and TNF-α. (A) qRT-PCR analysis of EMT marker expression (CDH1, VIM, and ACTA2). (B) Western blot showing the expression of E-cadherin, N-cadherin, vimentin, and α smooth muscle actin proteins in A549 cells stimulated with or without TGF-β1 and TNF-α. α-tubulin was used as the internal control. A549 cells were cultured as in Figure 1. N = 3 independent experiments. ** p <0.01; error bars represent SEM. Please click here to view a larger version of this figure.
Figure 5. Cells Undergoing EMT Acquired Contractility. A549 cells were plated at a density of 1.0 x 106 cells/dish in 10 cm dishes and incubated with or without 5 ng/ml TGF-β1 and 10 ng/ml TNF-α for 48 hr. Cells were then cast into 500 µl of medium containing 1.75 mg/ml collagen gel at a density of 3.0 × 105 cells/well in a 24-well plate. After gel formation, they were added to medium with or without 5 ng/ml TGF-β1 and 10 ng/ml TNF-α in 60 mm dishes and incubated for 72 hr followed by imaging (A). Gel sizes were measured after 0, 24, 48, and 72 hr using an image analysis system. N = 9 independent experiments (B). ** p <0.01; error bars represent SEM. Please click here to view a larger version of this figure.
Gene Name | Forward 5'→3' | Reverse 5'→3' | ||
ACTA2 | GCACCCAGCACCATGAAGA | ACCGATCCAGACAGAGTATTT | ||
GAPDH | GGTGAAGGTCGGAGTCAACGGA | GAGGGATCTCGCTCCTGGAAGA | ||
VIM | GACAATGCGTCTCTGGCACGTCTT | TTCTTCTGCCTCCTGCAGGTTCTT | ||
CDH1 | CCCATCAGCTGCCCAGAAAATGAA | CTGTCACCTTCAGCCATCCTGTTT |
Table 1. Primer Sequences. Primer sequences used for qRT-PCR. GAPDH was used as internal control.
Lysis Buffer: RIPA Buffer | |
20 mM Tris-HCl pH 7.5 | |
150 mM NaCl | |
1 mM EDTA | |
1% Polyoxyethylene (9) octyiphenyl ether | |
0.1% Na-deoxycholate | |
0.1% SDS | |
Blocking Buffer | |
1% Blocking reagent in wash buffer | |
Wash buffer: TBST buffer | |
NaCl | 45 g |
1 M Tris pH 7.4 | 50 ml |
Polyoxyethylene (20) Sorbitan monolaurate | 2.5 ml |
Distill Water | add to 5 L |
Total | 5 L |
Table 2. The Components of Buffers Used. The components of lysis, blocking buffer and wash buffer.
The protocol developed in this study comprises two steps. The first step is performed to induce EMT, while the second step is the gel contraction assay. Since it is important to confirm that cells underwent EMT, step 2 provides an excellent complement to the morphological and gene expression changes. Previous studies showed that EMT of A549 cells was induced by TGF-β1 only24; however, as we have reported previously10, TNF-α treatment enhances EMT and the acquisition of mesenchymal cell markers. It is thought that the mechanisms of TGF-β-mediated EMT is smad-dependent25. TNFα enhances TGF-β1-induced EMT that leads to enhancement of gel contraction. It has been reported that the mechanisms of TNFα for enhancement of TGF-β1-induced EMT are not only phosphorylation of smad2 linker region, but also MAPK signaling regulation26. Therefore, the protocol developed in this study included stimulation by both TGF-β1 and TNF-α.
The embedding of cells that underwent EMT into the type I collagen gel, and floating on the medium, are central aspects of this assay (step 4). Because the gels are soft and easily damaged, and have different dimensions on each side, extreme caution is required when applying the gels to the medium and measuring their sizes. If it is difficult to carry out this step, there is an alternative method to measure the gel sizes in the well without moving the gels into 60 mm dish27,28. There are several common problems, the first problem is that the collagen gels easily gelate at RT, so the gels often deform as mentioned in step 4.7. Therefore, the plate must be gently shaken after casting the gels into wells to make sure they take on a neat cylindrical form. The second problem is that if any air bubbles enter the gels during gelation, then the size of the gels will be uneven. Be careful not to allow any air bubbles to contaminate the gels. There are two main differences between original method and this method. The first differences is that the final concentration of collagen gels of original method is 0.75 mg/ml but that of this method is 1.75 mg/ml in order to allow the gels to contract more than they do with the original method. The second differences is that the original method uses serum free medium for gel floating medium but this method uses 1% FBS in the gel floating medium in order to keep cell viability and maintain cell contractility.
The gel contraction assay originally developed for fibroblasts is an ideal in vitro model for evaluating the contractility of cells that contribute to the process of wound healing and fibrosis 13. The attachment of fibroblasts to type 1 collagen is supposed to produce mechanical tensions that consequently leads to a reduction in the size of the collagen gels. Additionally, this assay has recently been used as an in vitro model for studying the contraction of airway cells in inflammatory diseases, including bronchial asthma and COPD29-31.
The gel contraction assay is comparable to other assays, such as cell migration assays, in that it does not require specific devices and exhibits high quantitative reproducibility. However, there are few reports applying the gel contraction assay for evaluating EMT32. In this study, gels containing cells that underwent EMT significantly decreased in size from 24 to 72 hr after gelation, indicating cell contraction. There are however limitations to this method. The first is that in this assay, the size change of the gels show the sum of contractility of all cells in the gels. However, it is difficult to evaluate single cell contractility in the gels using this assay. The second is that A549 cells is a cancer cell line, not normal human epithelial cells. Therefore, it is difficult to extrapolate our results directly to the pathogenesis of pulmonary fibrosis. However, A549 cells are widely used to study the functions of airway epithelial cells, and several studies yielded evidence of EMT by using A549 cells as a model of pulmonary fibrosis 33,34.
In summary, the type I collagen gels containing mesenchymal cells that underwent EMT were reduced in size, indicating contraction of those cells. Thus, the gel contraction assay should be considered as an extended in vitro assay to evaluate acquisition of contractile function in the cells through EMT process.
The authors have nothing to disclose.
We thank Dr. Tadashi Koyama for technical help. This work was supported in part by JSPS KAKENHI Grant Numbers 23249045, 15K09211, 15K19172; a grant to the Respiratory Failure Research Group from the Ministry of Health, Labour and Welfare, Japan; a grant for research on allergic disease and immunology, Japan.
DMEM | sigma aldrich | 11965-092 | For A549 medium |
FBS | GIBCO | 10437 | |
Transforming Growth Factor-β1, Human, recombinant | Wako Laboratory chemicals | 209-16544 | |
Recombinant Human TNF-α | R&D systems | 210-TA/CF | |
E-Cadherin (24E10) Rabbit mAb | Cell Signaling Technology | #3195 | 1:3000 dilution |
Vimentin (D21H3) Rabbit mAb | Cell Signaling Technology | #5741 | 1:3000 dilution |
Anti-α-Tubulin antibody | sigma aldrich | T9026 | 1:10000 dilution |
Monoclonal Anti-Actin, α-Smooth Muscle antibody | sigma aldrich | A5228 | 1:10000 dilution |
Anti-N-cadherin antibody | BD Transduction Laboratories | #610920 | 1:1000 dilution |
Anti-Mouse IgG, HRP-Linked Whole Ab Sheep (secondary antibody) | GE Healthcare | NA931-100UL | 1:20000 dilution |
Anti-Rabbit IgG, HRP-Linked Whole Ab Donkey (secondary antibody) | GE Healthcare | NA934-100UL | 1:20000 dilution |
blocking reagent | GE Healthcare | RPN418 | 2% in TBS-T |
6 Well Clear Flat Bottom TC-Treated Multiwell Cell Culture Plate, with Lid | corning | #353046 | |
100 mm cell culture dish | TPP | #93100 | |
DMEM, powder | life technologies | 12100-046 | For 4×DMEM |
type 1 collagen gel | Nitta gelatin | Cellmatrix type I-A | |
24 well cell culture plate | AGC TECHNO GLASS | 1820-024 | |
Gel Documentation System | ATTO | AE-6911FXN | Gel imager |
gel analyzing software | ATTO | Densitograph, ver. 3.00 | analysing software bundled with AE-6911FXN |
Trypsin-EDTA (0.05%), phenol red | life technologies | 25300054 | |
24 Well Plates, Non-Treated | IWAKI | 1820-024 | |
Trypan Blue Solution, 0.4% | life technologies | 15250-061 | |
RNA extraction kit | Qiagen | 74106 | |
reverse transcriptase | life technologies | 18080044 | |
real time PCR system | Stratagene | Mx-3000P | |
SYBR green PCR kit | Qiagen | 204145 | |
Protease Inhibitor Cocktail (100X) | life technologies | 78429 | |
PVDF membrane | ATTO | 2392390 | |
protein assay kit | bio-rad | 5000006JA | |
polyacrylamide gel | ATTO | 2331810 | |
western blotting detection reagent | GE Healthcare | RPN2232 | |
cold CCD camera | ATTO | Ez-Capture MG/ST | |
Trypsin inhibitor | sigma aldrich | T9003-100MG | |
Polyoxyethylene (20)Sorbitan Monolaurate | Wako Laboratory chemicals | 163-11512 | |
polyoxyethylene (9) octyiphenyl ether | Wako Laboratory chemicals | 141-08321 |